Paper24065243
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
Copelan EA and 37 others. Blood, 2013. Cited by 143 papers, by iCite.
Cite this record
ConductScience Library. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Papers, record 24065243. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24065243
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
- PubMed
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics25
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Leukemia, Myeloid | Major topic |
| Whole-Body Irradiation | Major topic |
| Acute Disease | |
| Adolescent | |
| Adult | |
| Busulfan | |
| Child | |
| Child, Preschool | |
| Combined Modality Therapy | |
| Cyclophosphamide | |
| Disease-Free Survival | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Multivariate Analysis | |
| Remission Induction | |
| Siblings | |
| Time Factors | |
| Transplantation, Homologous | |
| Treatment Outcome | |
| Unrelated Donors | |
| Young Adult |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| T32 HL007899 | NHLBI NIH HHS | United States | T32HL007899 | PubMed | NIH RePORTER |
| U01 HL069294 | NHLBI NIH HHS | United States | U01HL069294 | PubMed and NIH | NIH RePORTER |
| U24 CA076518 | NCI NIH HHS | United States | U24CA076518 | PubMed | NIH RePORTER |
| 5U01HL069294 | NHLBI NIH HHS | United States | U01HL069294 | PubMed and NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 24311716 | Busulfan or TBI: answer to an age-old question. | https://conductscience.org/library/papers/24311716 |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10090927 | Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. | Blood | 1999 | https://conductscience.org/library/papers/10090927 | PubMed |
| 2 | 10800057 | The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. | Bone Marrow Transplant | 2000 | https://conductscience.org/library/papers/10800057 | PubMed |
| 3 | 381925 | Marrow transplantation for acute nonlymphoblastic leukemia in first remission. | N Engl J Med | 1979 | https://conductscience.org/library/papers/381925 | PubMed |
| 4 | 15126320 | The impact of low-dose busulfan on clonal dynamics in nonhuman primates. | Blood | 2004 | https://conductscience.org/library/papers/15126320 | PubMed |
| 5 | 11939604 | Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. | Biol Blood Marrow Transplant | 2002 | https://conductscience.org/library/papers/11939604 | PubMed |
| 6 | 7050046 | Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. | Int J Radiat Oncol Biol Phys | 1982 | https://conductscience.org/library/papers/7050046 | PubMed |
| 7 | 15166618 | Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. | Anticancer Drugs | 2004 | https://conductscience.org/library/papers/15166618 | PubMed |
| 8 | 18690856 | Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. | Curr Clin Pharmacol | 2007 | https://conductscience.org/library/papers/18690856 | PubMed |
| 9 | 8167351 | A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. | Blood | 1994 | https://conductscience.org/library/papers/8167351 | PubMed |
| 10 | 7917905 | Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs. | Br J Cancer | 1994 | https://conductscience.org/library/papers/7917905 | PubMed |
| 11 | 2591002 | Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2591002 | PubMed |
| 12 | 1586710 | Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. | Blood | 1992 | https://conductscience.org/library/papers/1586710 | PubMed |
| 13 | 7825973 | Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). | Anticancer Res | 1994 | https://conductscience.org/library/papers/7825973 | PubMed |
| 14 | 1859895 | Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. | Blood | 1991 | https://conductscience.org/library/papers/1859895 | PubMed |
| 15 | 16641398 | Hematopoietic stem-cell transplantation. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16641398 | PubMed |
| 16 | 2224134 | Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. | Blood | 1990 | https://conductscience.org/library/papers/2224134 | PubMed |
| 17 | 12149198 | Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. | Blood | 2002 | https://conductscience.org/library/papers/12149198 | PubMed |
| 18 | 12374454 | Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. | Biol Blood Marrow Transplant | 2002 | https://conductscience.org/library/papers/12374454 | PubMed |
| 19 | 6996481 | Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. | Am J Med | 1980 | https://conductscience.org/library/papers/6996481 | PubMed |
| 20 | 8201385 | Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. | J Clin Oncol | 1994 | https://conductscience.org/library/papers/8201385 | PubMed |
Cited by80
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 143 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42819397 | The complications of irradiation or busulfan for CAYA before hematopoietic stem cell transplantation: a systematic review and meta-analysis. | Front Pediatr | 2026 | https://conductscience.org/library/papers/42819397 | PubMed |
| 42477157 | Allogeneic hematopoietic cell transplantation from haploidentical donors with total body irradiation versus chemo-based regimens for adult AML patients in first complete remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/42477157 | PubMed |
| 42469396 | Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/42469396 | PubMed |
| 41949966 | [Allogeneic hematopoietic stem cell transplantation in children's acute myeloblastic leukemia: Survival and relapse]. | Tunis Med | 2025 | https://conductscience.org/library/papers/41949966 | PubMed |
| 41730941 | Busulfan resistance in AML is associated with changes in mitochondrial copy number and lipid metabolism. | Sci Rep | 2026 | https://conductscience.org/library/papers/41730941 | PubMed |
| 41152589 | Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission: a multicenter study from the EBMT PDWP. | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/41152589 | PubMed |
| 40514011 | Seizure Prophylaxis and its Impact on Busulfan Pharmacokinetics and Dosing in a Novel Timed Sequential Protocol: MD Anderson Experience. | Transplant Cell Ther | 2025 | https://conductscience.org/library/papers/40514011 | PubMed |
| 40255903 | Optimizing treatment efficacy and fertility preservation in patients undergoing hematopoietic stem cell transplantation: A narrative review of ovarian shielding with total-body irradiation or treosulfan-based conditioning regimens. | Reprod Med Biol | 2025 | https://conductscience.org/library/papers/40255903 | PubMed |
| 39168989 | Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial. | Blood Cancer J | 2024 | https://conductscience.org/library/papers/39168989 | PubMed |
| 38702400 | Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients. | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/38702400 | PubMed |
| 38651157 | Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis. | Front Oncol | 2024 | https://conductscience.org/library/papers/38651157 | PubMed |
| 38438648 | Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1. | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/38438648 | PubMed |
| 37627199 | Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37627199 | PubMed |
| 37491812 | Saliva as a noninvasive sampling matrix for therapeutic drug monitoring of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation: A prospective population pharmacokinetic and simulation study. | CPT Pharmacometrics Syst Pharmacol | 2023 | https://conductscience.org/library/papers/37491812 | PubMed |
| 37283891 | Influence of SPIO labelling on the function of BMSCs in chemokine receptors expression and chemotaxis. | PeerJ | 2023 | https://conductscience.org/library/papers/37283891 | PubMed |
| 36966213 | Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy. | Bone Marrow Transplant | 2023 | https://conductscience.org/library/papers/36966213 | PubMed |
| 36505853 | Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies. | Front Oncol | 2022 | https://conductscience.org/library/papers/36505853 | PubMed |
| 36357773 | Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis. | Bone Marrow Transplant | 2023 | https://conductscience.org/library/papers/36357773 | PubMed |
| 35610308 | A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. | Bone Marrow Transplant | 2022 | https://conductscience.org/library/papers/35610308 | PubMed |
| 35340233 | Two Different Transplant Preconditioning Regimens Combined with Irradiation and Chemotherapy in the Treatment of Childhood Leukemia: Systematic Review and Meta-Analysis. | J Healthc Eng | 2022 | https://conductscience.org/library/papers/35340233 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24065243
GET https://conductscience.org/api/papers/v1/24065243/authors?page=2